Cambridge Innovation Capital (CIC), a venture capital firm focused on the UK’s deeptech and life sciences sectors, has announced a commitment of £100 million to invest in spinout companies emerging from the University of Cambridge. This announcement marks the launch of CIC’s third fund, Fund III, totaling £250 million, and signals its focus on nurturing early-stage science and technology ventures from one of the world’s most productive research ecosystems.
A major boost for University of Cambridge spinouts
CIC’s £100 million investment commitment is designed to harness the extraordinary scientific output of the University of Cambridge, whose spinouts contribute more than £23 billion annually to the UK economy. The university leads Europe in the number of unicorn companies produced, including global success stories such as ARM, Abcam, and Darktrace.
CIC’s Fund III aims to build on this legacy by identifying and supporting the next generation of high-growth startups emerging from academic research. This new funding will enable companies to progress from proof-of-concept to early-stage growth, accelerating their journey to market.
Launch of Entrepreneur in Residence programme
In parallel with the new fund, CIC is introducing a new Entrepreneur in Residence (EIR) programme in partnership with the University of Cambridge. The initiative is designed to commercialise high-potential intellectual property (IP) from within the university and increase the volume and quality of spinouts.
The EIR programme will maintain a rotating group of up to six seasoned executives, many of whom have previously scaled or exited successful deep tech or life sciences ventures. These experts will be matched with academics to help shape commercial strategy and accelerate company formation, providing vital early leadership to new ventures.
The EIR programme complements a growing suite of initiatives from the University of Cambridge designed to turn cutting-edge research into scalable startups. These include:
- Founders Programme – supporting the entrepreneurial journey of academic researchers.
- Technology Investment Fund (TIF) – a proof-of-concept fund aimed at de-risking early-stage research.
- Cambridge Enterprise Ventures (CEV) – a €115 million AUM investment vehicle recently topped up by an additional €34 million to enhance funding capacity for spinouts.
These combined iefforts create a coordinated ecosystem of support spanning ideation, early-stage funding, and company scaling.
Powering Cambridge’s innovation engine
Founded in 2013, CIC is deeply embedded in the Cambridge innovation ecosystem. With over £600 million in assets under management, the firm boasts a 12-year track record of backing science-led startups and seeing them through to successful exits. CIC invests across a broad spectrum of life sciences and deep tech areas, including cancer therapies, genomics, surgical robotics, AI, semiconductors, and quantum computing.
Previous success stories
CIC’s new funding and EIR programme will aim to replicate and extend recent spinout successes. Its portfolio includes some of the UK’s most notable startups as follows:
- Riverlane: A quantum computing pioneer raised over €105 million to lead in quantum error correction.
- T-Therapeutics: A biotech company focused on T cell therapies for cancer and autoimmune diseases.
- Cambridge GaN Devices (CGD): A company that designs energy-efficient power electronics and has secured over €43 million in funding.
Each of these companies originated from university IP and demonstrates the commercial power of Cambridge-led science when paired with the right funding and leadership.
Looking ahead
Beyond funding, the University of Cambridge is investing in physical infrastructure to support its spinout ambitions. Planned developments include four million square feet of high-tech facilities at Cambridge West and a new Innovation Hub in central Cambridge. These spaces will serve as launchpads for spinouts, startups, and entrepreneurial researchers, helping foster a dense and collaborative innovation environment.
With Fund III and the €115 million commitment to University of Cambridge spinouts, Cambridge Innovation Capital is doubling down on its mission to transform world-class research into high-impact commercial ventures. Through funding, mentorship, and ecosystem partnerships, CIC is helping shape the next wave of British deep tech and life sciences breakthroughs, right from the heart of Cambridge.
Andrew Williamson, Managing Partner, CIC, said: “Cambridge is at the forefront of innovation in DeepTech and life sciences. Our new EIR programme will provide academics and researchers with access to the £100 million we are committing to University of Cambridge spinouts as they continue to develop breakthrough technologies. This expansion of CIC’s long-standing partnership with the University of Cambridge, which provides unique access to the university’s academics and research, will help support the UK’s economic growth by developing the next generation of world-class companies.”
Dr Diarmuid O’Brien, Pro-Vice-Chancellor for Innovation at the University of Cambridge, said: “In 2024, the University of Cambridge created more spinout companies than any other university. It has also produced the most unicorns of any European ecosystem and generates £23 billion in economic interest linked to research and commercialisation each year. We are determined to do even more, and faster, through initiatives such as the new EIR programme and by attracting investment into our spinout companies working with partners like Cambridge Innovation Capital.”